# OnCo record brightpath-biotherapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/brightpath-biotherapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "brightpath-biotherapeutics" ;
  schema:name "BrightPath Biotherapeutics"@en ;
  schema:alternateName "BrightPath Bio"@en, "GreenPeptide"@en ;
  schema:description "BrightPath Biotherapeutics is a Japanese company making ready-made immune cell therapies grown from stem cells. Its lead product, BP2202, uses engineered natural killer T cells aimed at the BCMA protein on myeloma cells and is in a first US trial for myeloma that has returned or stopped responding."@en ;
  schema:url <https://onco.cc/companies/brightpath-biotherapeutics/>, <https://www.brightpathbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.brightpathbio.com/>, <https://www.brightpathbio.com/pipeline/bp2202.html>, <https://clinicaltrials.gov/study/NCT07667868> ;
  schema:addressCountry "JP" ;
  onco:cancers <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:targets <https://onco.cc/targets/bcma/> .